All of our cells produce tiny vesicles, or bubbles, ranging from 30 to 150 nanometers in diameter, known as exosomes. These structures play a multitude of roles within the body, acting as messengers that transport biological material – delivering signals, removing waste, and contributing to tissue repair, blood clotting, and immune system activation. Understanding exosomes is increasingly crucial as researchers uncover their involvement in both health and disease.
When Tumors Hijack Exosomes
Exosomes have been studied for approximately three decades, and are now a central focus of many research efforts. While essential for healthy bodily functions, they are also implicated in a variety of illnesses, including cardiovascular, neurodegenerative, and infectious diseases. Some viruses, such as hepatitis, even utilize exosomes to spread from cell to cell. However, their role in cancer is particularly concerning, as they contribute to what is known as immune evasion – hindering or redirecting the immune system’s response, preventing it from effectively recognizing and destroying cancerous cells.
In the context of cancer, exosomes essentially become tools for the tumor’s survival. They promote tumor growth, the formation of new blood vessels to feed the tumor, invasion of surrounding tissues, metastasis (spread to other parts of the body), and resistance to treatment. Critically, they also assist the tumor evade detection by the immune system. Researchers note that completely blocking exosome production throughout the body isn’t feasible, as all cells produce them and doing so would cause significant side effects.
Messengers That Change Sides
A recent study published in the Journal of Extracellular Vesicles suggests a potential solution: reprogramming tumor exosomes without halting their production altogether. The research focuses on a molecule called dendrogenin A (DDA), which appears capable of altering the message carried by these vesicles. “We are able to reprogram these exosomes so that they can effectively fight tumors and activate the immune system against the tumor,” explained Sandrine Silvente-Poirot.
According to the study, DDA enriches exosomes with specific lipids, allowing for their rapid and efficient capture by immune cells, particularly dendritic cells. These cells then activate T lymphocytes, which are capable of recognizing and destroying tumor cells. When researchers injected these reprogrammed exosomes into mice with melanoma or breast cancer, they observed a significant inhibition of tumor growth, and in some cases, complete tumor disappearance after just two injections. This effect was accompanied by an infiltration of the tumors by dendritic cells and T lymphocytes, indicating a cascade of immune activation. The DDA changes the nature of the exosomes, shifting them from tumor-promoting to immune-activating.
The study found that survival rates tripled in mice treated with both the reprogrammed exosomes and conventional immunotherapy. This is particularly significant, as immunotherapies are not universally effective, with 60 to 80 percent of patients not responding sufficiently to these treatments. This approach aims to enhance the efficacy of existing immunotherapies and improve treatment outcomes. Further research will focus on replicating these results in animal models of other cancers, and determining whether DDA-mediated exosome reprogramming can be successfully applied in humans, transforming cancer messengers into allies of the immune system.
À écouter
